Trial Profile
Efficacy in Controlling Glycaemia With Victoza (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Dapagliflozin; Empagliflozin; Gliclazide; Glimepiride; Linagliptin; Pioglitazone; Saxagliptin; Sitagliptin; Vildagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LIRA-PRIME
- Sponsors Novo Nordisk
- 25 Sep 2020 Primary endpoint has been met. (Time to Inadequate Glycaemic Control)
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association